Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of the drug, HuMax-CD4, in patients
with mycosis fungoides(MF) and sezary syndrome who are intolerant to or do not respond to
treatment with Targretin® and one other standard therapy.